|
WO2020245775A1
|
|
Crystalline forms of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol
|
|
WO2020161636A1
|
|
Purification of glp-1 analogues
|
|
WO2020144606A1
|
|
Preparative crystallization of recombinant human insulin
|
|
EP3806890A1
|
|
Method and use of controlling postprandial glucose levels in a subject
|
|
US2019169621A1
|
|
Targeted/immunomodulatory fusion proteins in combination with additional therapeutic agents and methods for making same
|
|
KR20200088307A
|
|
Synthesis of Icatibant
|
|
KR20200092945A
|
|
Lenalidomide Crystalline Form
|
|
KR20200092946A
|
|
Crystalline linagliptin intermediate and linagliptin manufacturing process
|
|
CN111386281A
|
|
Integrated automated filtration for separation, washing and drying of peptide crystals
|
|
WO2019021133A1
|
|
Peptide mapping method for sequence identification of insulin & insulin analogues
|
|
CN111108104A
|
|
Polymorphic forms of dasatinib
|
|
MX2019006711A
|
|
Synthesis of liraglutide.
|
|
WO2018096445A1
|
|
Stable formulation of recombinant humanized monoclonal antibody
|
|
CN110225925A
|
|
Glycoprotein deglycosylation rapidly and efficiently
|
|
KR20190077467A
|
|
Amorphous trisodium saccharide valsartan and its preparation method
|
|
KR20190066067A
|
|
Monoclonal Antibodies and Therapeutic Methods for the Treatment of Lupus
|
|
CA3076861A1
|
|
Use of itolizumab to reduce phosphorylation of cd6
|
|
WO2017221211A1
|
|
Process for the preparation of dapagliflozin and its solvate thereof
|
|
WO2017134592A1
|
|
Anti-cd20/immunomodulatory fusion proteins and methods for making same
|
|
AU2017208935A1
|
|
Bio-analytical method for insulin analogues
|
